Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.

التفاصيل البيبلوغرافية
العنوان:	Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
المؤلفون:	Ellingson BM; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Neuroscience Interdepartmental PhD Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California.; Department of Neurosurgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, California.; Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Hagiwara A; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Radiology, Juntendo University School of Medicine, Tokyo, Japan., Morris CJ; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Medical Scientist Training Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Cho NS; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Department of Bioengineering, Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California.; Medical Scientist Training Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Oshima S; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Sanvito F; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Oughourlian TC; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.; Neuroscience Interdepartmental PhD Program, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Telesca D; Department of Biostatistics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Raymond C; UCLA Brain Tumor Imaging Laboratory (BTIL), Center for Computer Vision and Imaging Biomarkers, University of California Los Angeles, Los Angeles, California.; Department of Radiological Sciences, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Abrey LE; F. Hoffman-La Roche, Ltd., South San Francisco, California., Garcia J; F. Hoffman-La Roche, Ltd., South San Francisco, California., Aftab DT; Exelixis, Alameda, California., Hessel C; Exelixis, Alameda, California., Rachmilewitz Minei T; VBL Therapeutics, Modi'in, Israel., Harats D; VBL Therapeutics, Modi'in, Israel., Nathanson DA; Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California., Wen PY; Center for Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Cloughesy TF; UCLA Neuro-Oncology Program, University of California Los Angeles, Los Angeles, California.; Department of Neurology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
المصدر:	Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2023 Oct 13; Vol. 29 (20), pp. 4186-4195.
نوع المنشور:	Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
اللغة:	English
بيانات الدورية:	Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE
أسماء مطبوعة:	Original Publication: Denville, NJ : The Association, c1995-
مواضيع طبية MeSH:	Glioblastoma/diagnostic imaging , Glioblastoma/drug therapy , Brain Neoplasms/diagnostic imaging , Brain Neoplasms/drug therapy, Humans ; Bevacizumab/therapeutic use ; Angiogenesis Inhibitors/therapeutic use ; Neoplasm Recurrence, Local/diagnostic imaging ; Neoplasm Recurrence, Local/drug therapy ; Irinotecan/therapeutic use ; Magnetic Resonance Imaging/methods
مستخلص:	Purpose: Antiangiogenic therapies are known to cause high radiographic response rates due to reduction in vascular permeability resulting in a lower degree of contrast extravasation. In this study, we investigate the prognostic ability for model-derived parameters describing enhancing tumor volumetric dynamics to predict survival in recurrent glioblastoma treated with antiangiogenic therapy. Experimental Design: N = 276 patients in two phase II trials were used as training data, including bevacizumab ± irinotecan (NCT00345163) and cabozantinib (NCT00704288), and N = 74 patients in the bevacizumab arm of a phase III trial (NCT02511405) were used for validation. Enhancing volumes were estimated using T1 subtraction maps, and a biexponential model was used to estimate regrowth (g) and regression (d) rates, time to tumor regrowth (TTG), and the depth of response (DpR). Response characteristics were compared to diffusion MR phenotypes previously shown to predict survival. Results: Optimized thresholds occurred at g = 0.07 months-1 (phase II: HR = 0.2579, P = 5 × 10-20; phase III: HR = 0.2197, P = 5 × 10-5); d = 0.11 months-1 (HR = 0.3365, P < 0.0001; HR = 0.3675, P = 0.0113); TTG = 3.8 months (HR = 0.2702, P = 6 × 10-17; HR = 0.2061, P = 2 × 10-5); and DpR = 11.3% (HR = 0.6326, P = 0.0028; HR = 0.4785, P = 0.0206). Multivariable Cox regression controlling for age and baseline tumor volume confirmed these factors as significant predictors of survival. Patients with a favorable pretreatment diffusion MRI phenotype had a significantly longer TTG and slower regrowth. Conclusions: Recurrent glioblastoma patients with a large, durable radiographic response to antiangiogenic agents have significantly longer survival. This information is useful for interpreting activity of antiangiogenic agents in recurrent glioblastoma. (©2023 American Association for Cancer Research.)
References:	J Clin Oncol. 2009 Oct 1;27(28):4733-40. (PMID: 19720927) Neuro Oncol. 2015 Sep;17(9):1188-98. (PMID: 26250565) JAMA Oncol. 2020 Jul 1;6(7):1003-1010. (PMID: 32437507) J Clin Oncol. 2013 Sep 10;31(26):3212-8. (PMID: 23940216) Clin Cancer Res. 2017 Oct 1;23(19):5745-5756. (PMID: 28655794) J Neurooncol. 2006 Jul;78(3):233-47. (PMID: 16612574) AJNR Am J Neuroradiol. 2014 Apr;35(4):673-9. (PMID: 24136647) Neuro Oncol. 2018 Sep 3;20(10):1411-1418. (PMID: 29660005) Nature. 1992 Oct 29;359(6398):845-8. (PMID: 1279432) Lancet Oncol. 2017 Jan;18(1):143-154. (PMID: 27979599) Neuro Oncol. 2018 Jan 22;20(2):249-258. (PMID: 29016998) Cancer J. 2012 Jan-Feb;18(1):45-50. (PMID: 22290257) J Clin Oncol. 2010 Jun 10;28(17):2817-23. (PMID: 20458050) Clin Cancer Res. 2020 Dec 15;26(24):6464-6474. (PMID: 32988968) PLoS One. 2016 May 27;11(5):e0156369. (PMID: 27232884) Radiology. 2014 Apr;271(1):200-10. (PMID: 24475840) Lancet Oncol. 2014 Aug;15(9):943-53. (PMID: 25035291) Cancer J. 2018 Jul/Aug;24(4):180-186. (PMID: 30119081) Sci Rep. 2020 Sep 9;10(1):14819. (PMID: 32908231) J Neurooncol. 2014 Feb;116(3):551-8. (PMID: 24318915) Neuro Oncol. 2022 Jun 1;24(6):1020-1028. (PMID: 34865129) Clin Cancer Res. 2014 Nov 15;20(22):5612-9. (PMID: 25398844) N Engl J Med. 2017 Nov 16;377(20):1954-1963. (PMID: 29141164) Neuro Oncol. 2020 Nov 26;22(11):1667-1676. (PMID: 32393964) J Clin Oncol. 2009 Feb 10;27(5):740-5. (PMID: 19114704) Neuro Oncol. 2020 May 15;22(5):705-717. (PMID: 31844890) Radiology. 2009 Jul;252(1):182-9. (PMID: 19561256) Clin Cancer Res. 2012 Apr 15;18(8):2374-81. (PMID: 22344231) Neuro Oncol. 2023 Jun 2;25(6):1017-1028. (PMID: 36617262) J Neurooncol. 2012 Jul;108(3):491-8. (PMID: 22426926)
معلومات مُعتمدة:	P50 CA211015 United States CA NCI NIH HHS; R01 CA270027 United States CA NCI NIH HHS; R01 NS078494 United States NS NINDS NIH HHS; T32 GM008042 United States GM NIGMS NIH HHS
سلسلة جزيئية:	ClinicalTrials.gov NCT00345163; NCT00704288; NCT02511405
المشرفين على المادة:	2S9ZZM9Q9V (Bevacizumab) 0 (Angiogenesis Inhibitors) 7673326042 (Irinotecan)
تواريخ الأحداث:	Date Created: 20230804 Date Completed: 20231026 Latest Revision: 20240414
رمز التحديث:	20240414
مُعرف محوري في PubMed:	PMC10592195
DOI:	10.1158/1078-0432.CCR-23-1235
PMID:	37540556
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1557-3265
DOI:	10.1158/1078-0432.CCR-23-1235